Monday, February 26, 2024
Diamyd Medical is a Stockholm-based, precision medicine company developing an antigen-specific immunotherapy for the treatment and prevention of (autoimmune) Type 1 Diabetes in a genetically defined responder group who represent about 40% of newly diagnosed Type 1 diabetes patients in the US and Europe. Diamyd Medial is currently conducting the first-ever precision medicine Phase 3 trial for the treatment of Type 1 Diabetes enrolling only likely responder patients.
CEO/Top Company Official
Ulf Hannelius, CEO Christoph Nowak, CBO/CMO
Lead Product in Development
Development Phase of Primary Product
Number Of Unlicensed Products